 Rosenlicht | Los Angeles Times – May 3, 2011
Abilify, the brand name of the drug aripiprazole, is an antipsychotic medication used to treat the acute phase of bipolar disorder as well as the maintenance phase — the period of time after a patient has improved and the focus turns toward preventing a relapse.
This second use of Abilify is the target of a biting review published Tuesday by Dr. Alexander Tsai of Harvard University and Dr. Nicholas Rosenlicht of UC San Francisco. The scientists set out to review data that justify the use of Abilify for the maintenance phase of bipolar disorder — and found very little.
Read full Los Angeles Times story |